Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Allergy Asthma Clin Immunol
.
2017 Nov 3:13:45.
doi: 10.1186/s13223-017-0217-6.
eCollection 2017.
Authors
I J Pouliquen
1
,
P Howarth
2
,
D Austin
1
,
G Gunn
3
,
E Meyer
3
,
R G Price
4
,
E Bradford
5
Affiliations
1
Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Uxbridge, UK.
2
Respiratory Franchise, GlaxoSmithKline, Brentford, UK.
3
Immunogenicity and Clinical Immunology, GlaxoSmithKline, King of Prussia, PA USA.
4
Clinical Statistics, GlaxoSmithKline, Uxbridge, UK.
5
Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC USA.
PMID:
29118815
PMCID:
PMC5668989
DOI:
10.1186/s13223-017-0217-6
No abstract available
Keywords:
Case report; IL-5; Mepolizumab; OCS; Severe eosinophilic asthma.